Spots Global Cancer Trial Database for Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Official Title: Phase II Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Study ID: NCT01289678
Conditions
Interventions
Study Description
Brief Summary: Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment during lymphocyte recovery.
Detailed Description: Upon lymphocyte recovery after myeloablative induction standard chemotherapy pulse Interleukin-2 administered
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Leo W. Jenkins Cancer Center, Greenville, North Carolina, United States
Contact Details
Name: Paul Walker, MD
Affiliation: The Brody School of Medicine at East Carolina University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
